4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on May 12, 2026, its board compensation committee granted 141,100 Restricted Stock Units (RSUs) to 14 new non-executive employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on May 12, 2026, its board compensation committee granted 141,100 Restricted Stock Units (RSUs) to 14 new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
Details
News Market Reaction – FDMT
On May 18, the first trading day after this news, FDMT closed 8.58% below the previous close.
Data tracked by StockTitan Argus for the May 18 session.
Key Figures
- RSU grants
- 141,100 RSUs
- Granted to 14 new non-executive employees on May 12, 2026
- New employees
- 14 employees
- Recipients of inducement RSU awards
- Shelf registration
- $400.0 million
- Total securities registered on S-3 shelf filed May 7, 2026
- Unsold securities
- $200.0 million
- Previously registered unsold securities included in shelf
- Additional securities
- $200.0 million
- Approximate additional securities registered on the shelf
- Cash balance
- $457.6 million
- Cash, cash equivalents and marketable securities as of Mar 31, 2026 (10-Q)
- Net loss
- $68.8 million
- Net loss for quarter ended Mar 31, 2026 (10-Q)
- R&D expense
- $65.0 million
- Research and development spending for quarter ended Mar 31, 2026 (10-Q)
Historical Context
-
Q1 2026 results with strong cash runway and late-stage pipeline progress.
-
Announcement of May 2026 healthcare conference presentations and meetings.
-
April 14, 2026 RSU grants to five new non-executive employees.
-
Full-year 2025 results, Otsuka partnership, and strong balance sheet update.
-
Announcement of March 2026 investor meetings and ophthalmology conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units (rsus) financial
nasdaq global market regulatory
employment inducement award plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 12, 2026, the compensation committee of the Company’s board of directors granted 14 new non-executive employees 141,100 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.